Skip to content

Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up

A Cluster Randomized Clinical Trial of Umbilical Cord Milking Versus Early Cord Clamping on Short and Long-term Outcomes in Neonates Who Are Non-Vigorous at Birth

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03682042
Acronym
CORDMILK-FU
Enrollment
3442
Registered
2018-09-24
Start date
2022-10-17
Completion date
2027-10-30
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Birth Asphyxia, Hypoxic-Ischemic Encephalopathy

Keywords

Placental transfusion

Brief summary

An extension of the CORDMILK trial, the CORDMILK follow-up trial will evaluate the neurodevelopmental outcomes at 22-26 months age of term/late preterm infants who were non-vigorous at birth and received umbilical cord milking (UCM) or early cord clamping (ECC).

Detailed description

The CORDMILK Follow-up trial will examine the difference in survival and neurodevelopmental impairment of infants who were non-vigorous at birth and enrolled in the CORDMILK trial. The difference in survival and neurodevelopmental impairment in infants who received UCM and ECC will be assessed using standardized neurological and developmental assessment tools at 22-26 months of age.

Interventions

OTHERUmbilical Cord Milking

At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.

Sponsors

Nemours Children's Clinic
Lead SponsorOTHER
Sharp HealthCare
CollaboratorOTHER
Thomas Jefferson University
CollaboratorOTHER
University of California, San Diego
CollaboratorOTHER
St. Louis University
CollaboratorOTHER
KLE Academy of Higher Education and Research (Deemed- to- be-University), Jawaharlal Nehru Medical College (JNMC), Belagavi, India
CollaboratorUNKNOWN
Government Medical College, Nagpur
CollaboratorINDUSTRY
Daga Memorial Maternity and Children's Hospital, Nagpur, India
CollaboratorUNKNOWN
Mahatma Gandhi Institute of Medical Sciences
CollaboratorOTHER
Karnataka Institute of Medical Sciences, Hubbali, India
CollaboratorUNKNOWN
All India Institute of Medical Sciences
CollaboratorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Indira Gandhi Government Medical College & Hospital, Nagpur, India
CollaboratorUNKNOWN
Pimpri Chinchwad Municipal Corporation's Post-Graduate Institute, Yashwantrao Chavan Memorial Hospital, Pune, India
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Neurodevelopmental providers will be blinded to the randomization of the toddler during the examination.

Intervention model description

Neurodevelopmental assessments will be done at 2 years of age (22-26 months) for subjects who were randomized to receive either early cord clamping or umbilical cord milking as part of the CORDMILK trial.

Eligibility

Sex/Gender
ALL
Age
22 Months to 26 Months
Healthy volunteers
No

Inclusion criteria

* Enrolled in CORDMILK trial * Non-vigorous at birth

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Neurodevelopmental Outcome at 2 Years of Age22-26 monthsNeurodevelopmental assessment will be performed by the trained and experienced examiner who will be blinded to the interventions. Severe neurodevelopmental impairment will be defined having at least one of the following: BSID (IV) composite cognitive score \<70, GMFCS level 3-5, blindness (vision \<20/200), or hearing impairment requiring hearing aids/cochlear implant. Moderate neurodevelopmental impairment will be defined as having a cognitive composite score 70-84, GMFCS level 2, unilateral blindness (vision/20/200 in only one eye), or hearing impairment with no amplification/cochlear implant.

Secondary

MeasureTime frameDescription
Neurodevelopmental Outcome at 1 Year of Age10-14 monthsNeurodevelopmental assessment will be performed by the trained and experienced examiner who will be blinded to the intervention using the Developmental Assessment Scales for Indian Infants (DASII). DAASI provides developmental motor quotient (DMoQ), developmental mental quotient (DMeQ), and composite developmental quotient (DQ). With a mean DQ of 100 and standard deviation (SD) of 15, 1SD and 2SD below mean correspond to DQ of 85 and 70, respectively. A DMoQ, DMeQ or DQ score of \<70 (2SD) is considered as neurodevelopmental impairment.

Countries

India

Contacts

PRINCIPAL_INVESTIGATORZubair Aghai, MD

Nemours Children's Clinic

PRINCIPAL_INVESTIGATORAnup Katheria, MD

Sharp Mary Birch Hospital for Women & Newborns

PRINCIPAL_INVESTIGATORSangappa Dhaded

KLE Academy of Higher Education and Research

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026